Anticoagulant — Indirect Thrombin Inhibitor
Pregnancy: C
Unfractionated Heparin (IV)
Brand names: Heparin Sodium
Adult dose
Dose: 5000 units IV bolus then 18 units/kg/h infusion; adjust to APTT ratio 1.5–2.5
Route: intravenous
Frequency: continuous infusion (bolus then infusion)
Max: Protocol dependent (APTT-guided)
Use weight-based dosing nomogram; APTT-guided dose adjustment; check APTT 6h after initiation and after dose change
Paediatric dose
Route: IV
Frequency: continuous infusion
Max: 20 units/kg/h
Concentration: 1000 units/mL or 5000 units/mL (dilute for neonates) units/hour/ml
Anti-Xa monitoring preferred in neonates; target APTT ratio 1.5–2.5; check APTT 4h post-initiation
Dose adjustments
Renal
No dose adjustment required (hepatic metabolism, renal excretion minor)
Hepatic
Use with caution in severe hepatic impairment
Clinical pearls
- Only anticoagulant in UK practice that is fully reversed by protamine sulphate (1 mg per 100 units)
- HIT Type 2: immune-mediated; platelet drop >50% after day 5 of heparin; 4T score for probability; switch to argatroban
- Advantage over LMWH: immediate reversal, short half-life (90 min IV), APTT monitoring
Contraindications
- Active haemorrhage
- History of HIT
- Thrombocytopenia (<100 × 10⁹/L)
- Recent neurosurgery or ophthalmological surgery
Side effects
- Bleeding
- HIT (Type 1 — benign, Type 2 — thrombotic: serious)
- Osteoporosis (long-term)
- Hyperkalaemia
- Elevated LFTs
- Hypersensitivity
Interactions
- Anticoagulants/antiplatelets (bleeding)
- GTN IV (reduces heparin effect)
- Penicillins (may partially antagonise)
Monitoring
- APTT ratio (target 1.5–2.5; 6h after initiation, then daily when stable)
- Platelet count every 2–3 days (HIT monitoring)
- Serum potassium
Reference: BNFc; BNF 86; BCSH HIT guidelines; NICE NG158. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- MELD-Na Score · Liver Disease
Pathways
- Peripheral Arterial Disease · NICE NG19 2012 / ESVS 2017
- Carotid Artery Disease · NICE CG68 / ESVS 2018
- Varicose Veins Management · NICE CG168 2013
- Venous Leg Ulcer Management · NICE NG204 2022
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE